Background. It has recently been demonstrated that myocardial ischemia and reperfusion results in a marked decrease in the release of nitric oxide (NO) by the coronary endothelium. NO may possess
Pr revious studies of myocardial ischemia and reperfusion have demonstrated marked impairment of endothelium-dependent relaxation of the coronary vasculature. Studies by Ku 
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The biological profile of EDRF is nearly identical to that of nitric oxide (NO),7 and experimental evidence indicates that EDRF is either NO or a nitroso compound that releases NO.8 At physiological concentrations, NO possesses a number of properties making it ideal for the treatment of myocardial ischemia-reperfusion injury. Specifically, NO exerts potent vasodilator actions,9-11 antiplatelet activity,'2 and inhibition of both neutrophil aggregation13 and adhesion.14 Normally, NO is released basally by the endothelial cells of the coronary vasculature and inhibits platelet and neutrophil adhesion to the endothelium, thereby preventing thrombus formation and microvascular embolization. However, after ischemia and reperfusion, neutrophils may become activated within the ischemic-reperfused zone, and their adherence to vascular endothelium may progress unopposed because of the loss of antiaggregatory effects of NO. Therefore, it is likely that diminished NO release by the injured coronary vascular endothelium is a crucial event in the pathogenesis of myocardial ischemia-reperfusion (MI-R) injury.1s A number of agents16-19 including L-arginine, perfluorochemical, human recombinant superoxide dismutase, and taprostene (a stable prostacyclin analog) administered just before or at the time of reperfusion have been shown to preserve agonist-mediated release of NO from the coronary vascular endothelium. This preserved endothelial function was associated with a reduction of postischemic infarct size. Furthermore, Johnson and coworkers20 demonstrated that authentic NO, administered at a subvasodilator concentration at reperfusion, significantly reduced myocardial necrosis in cats subjected to MI-R. However, because of the difficulties of administering NO in the gaseous form, the administration of authentic NO is impractical for clinical use. Therefore, pharmacological agents that release NO under physiological conditions may provide a more practical therapeutic approach to cardioprotection from MI-R injury. N-Nitratopivaloly-S-(N'-acetylalanyl)-cysteine ethyl ester (SPM-5185) is a cysteine-containing organic NO donor compound (Fig 1) . Accordingly, the purposes of the following study were to (1) examine the cardioprotective effects of SPM-5185 in MI-R and (2) elucidate the mechanism(s) of any observed cardioprotection.
Methods

Experimental Procedure
Twenty-eight heartworm-free dogs of either sex (weight, 17.0 to 30.0 kg) were initially anesthetized with 2% sodium thiamylal (20 mg/kg IV) supplemented with fentanyl citrate (25 ,ug/kg) and diazepam (5 mg bolus) administered intravenously as needed to maintain deep anesthesia. The dogs were endotracheally intubated and ventilated with a Harvard volume-cycled respirator using oxygen-enriched room air. The oxygen flow was adjusted to maintain the arterial oxygen tension above 100 mm Hg, and the ventilatory rate was set to maintain arterial carbon dioxide tension between 30 and 40 mm Hg. Arterial pH was adjusted to 7.40+0.05 using sodium bicarbonate (Abbott Laboratories, North Chicago, Ill) as necessary. A standard lead II electrocardiogram was monitored throughout the experimental protocol as an indication of the severity of myocardial ischemia. Polyethylene catheters were inserted into the right femoral artery for blood sampling and into both femoral veins for fluid and drug administration. Additionally, the left femoral artery was cannulated with a 13-F infant vent catheter (DLP, Inc, Grand Rapids, Mich) to provide an arterial blood source for the extracorporeal coronary artery perfusion circuit at the time of reperfusion.
Through a median sternotomy incision, the pericardium was incised and tented to cradle the heart. Millar MPC-500 temperature-compensating solid-state catheter-tipped transducers (Millar Instruments, Houston, Tex) were placed in the proximal aorta through the right internal mammary artery and in the left ventricular cavity through an apical stab wound to measure arterial and left ventricular pressures, respectively. A polyethylene cannula was inserted into the left atrium for administration of radioactive microspheres. A 1-cm portion of the left anterior descending (LAD) coronary artery distal to the first marginal branch was dissected and loosely encircled with 3-0 silk suture for subsequent LAD coronary artery occlusion. A small right ventricular branch of the LAD artery distal to the site of occlusion was dissected free and cannulated with a 2-F Millar solid-state catheter-tipped transducer (Millar Instruments) to monitor LAD coronary artery pressure. A pair of 5-MHz piezoelectric ultrasonic crystals, 2.5 mm in diameter, were implanted in the subendocardium of the myocardium perfused by the LAD (ischemicreperfused zone) and the circumflex coronary artery, oriented parallel to the direction of the circumferential fibers to measure instantaneous segment length using a sonomicrometer (model 120, Triton Technology, San Diego, Calif).
Experimental Protocol
The dogs were systemically heparinized with 10 000 U sodium heparin (Lymphomed, Rosemont, Ill), which was supplemented every 60 minutes to achieve an activated clotting time >400 seconds. All animals were allowed to stabilize for 30 Peripheral blood (500 mL) was collected from the femoral artery of seven additional pentobarbital-anesthetized (30 mg/kg IV) dogs (weight, 15.0 to 17.0 kg) and anticoagulated with citrate-phosphate-dextrose solution (Sigma Chemical Co) (1.4:10, vol:vol anticoagulant to whole blood) into round-bottom polycarbonate centrifuge tubes (Nalge, Rochester, NY). PMNs were isolated using the technique of Lafrado and colleagues.32 Platelet-rich plasma (PRP) was obtained by centrifuging blood at 400g for 10 minutes. The PRP was then centrifuged at 2500g for 10 minutes to obtain platelet-poor plasma (PPP). The PPP was then mixed with isotonic Percoll (9 vol Percoll:1 vol 1.5 M NaCl, Sigma Chemical Co) to produce Percoll-PPP density gradients of 80%, 62%, and 50%. Five milliliters of 4% dextran (average molecular weight, 6000 to 90 000, Sigma Chemical Co) was added to the erythrocyteleukocyte pellet from the initial 400g centrifugation. After mixture by inversion, the erythrocytes were allowed to settle for 50 minutes. The leukocyte-rich upper layer was collected and centrifuged at 1500g for 10 minutes. The pellets were resuspended in 1 mL of 0.9% NaCl and layered onto the Percoll: PPP gradient. Centrifugation was then performed at 400g for 40 minutes at 4°C in a Sorvall RC2-B refrigerated centrifuge (Ivan Sorvall, Inc, Newton, Conn). PMNs were collected from the 62% to 82% interface and washed twice with 0.9% NaCI before being assayed for viability using trypan blue exclusion. PMN Fig 1) ; (5) PMNs, LTB4 (100 nmol/L), and MAb R15.7 (20 mg/mL) (Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn), a monoclonal antibody to the common 13-chain of the CD11/CD18 neutrophil adhesion complex; and (6) PMNs, LTB4 (100 nmol/L), and nitroglycerin (NTG, 500 nmol/L). PMNs were added to the dishes containing unstimulated coronary artery rings. The dishes were placed in a Dubnoff metabolic shaking incubator and shaken for 20 minutes at 0.5 Hz at 37°C. After 20 minutes of incubation, coronary artery segments were removed and dipped three to four times in fresh Krebs-Henseleit solution and were then placed on a glass slide with the endothelial side up. The number of PMNs adhering to the endothelial surface in five separate microscopic fields were counted under epifluorescent microscopy at a magnification x100.
To study the adherence of unstimulated PMNs to ischemic-reperfused coronary arterial segments, 4 additional dogs were subjected to 60 minutes of LAD coronary artery occlusion and 120 minutes of reperfusion. The ischemic-reperfused LAD coronary artery was carefully removed from the hearts and placed in warmed Krebs-Henseleit solution. Autologous PMNs were isolated as described above from these dogs before ischemia, and the PMNs and coronary arterial segments were randomly divided into the following groups: (1) PMNs alone; (2) PMNs and SPM-5185 (500 nmol/L); (3) PMNs and SPM-5267 (500 nmol/L); (4) PMNs and NTG (500 nmol/L); (5) PMNs and MAb R15.7 (20 ,ug/mL). After 20 minutes of incubation in a shaker bath, the coronary artery segments were removed, gently washed, and counted under epifluorescent mi-Neutrophil-Induced Contraction and Endothelial Dysfunction Assay Canine PMNs were isolated from the arterial blood of 6 sodium pentobarbital-anesthetized (35 mg/kg IV) dogs as previously described. During the PMN isolation, the LAD coronary artery was carefully removed and placed into 370C Krebs-Henseleit solution. The LAD coronary artery was cleaned of fat and connective tissue and cut into rings 2 to 3 mm in width and then mounted on stainless steel hooks and placed into 10-mL organ chambers (Radnotti Glass, Monrovia, Calif). The coronary artery rings were initially stretched to give a preload of 1.0 g of force and allowed to equilibrate for 90 to 120 minutes until a stable baseline was achieved. After this equilibration period, the coronary artery rings were exposed to 100 nmol/L U-46619 (9,11-methanoepoxy-PGH2, The Upjohn Co, Kalamazoo, Mich) to precontract the vascular ring. Once a stable contraction was observed, acetylcholine (ACh) was added to the bath to achieve the following final concentrations: 0.1, 1, 10, and 100 nmol/L. After In additional control coronary artery rings without PMNs, the dose-dependent vasorelaxing effects of SPM-5185 and SPM-5267 were studied after precontraction of the coronary rings with U-46619.
Statistical Analysis
All data were analyzed with the STATISTICAL ANALYSIS SYSTEM program (PC-SAS; SAS Institute, Cary, NC). Time-related differences and group-time interactions were analyzed by two-way ANOVA for repeated measures followed by Holm's sequential rejection method to isons to <.05. 34 Hemodynamics, infarct size, PMN adherence, and MPO data were analyzed for group differences by ANOVA. The sources of differences were located with Duncan's multiple range post hoc test. All data are presented as mean±SEM.
Results
Cardiac Hemodynamic Data
Hemodynamic data including heart rate (HR), left ventricular pressures, mean arterial blood pressure (MABP), mean LAD pressure, and pressure rate index (PRI), are shown in Table 1 . No significant group differences were observed in MABP, dP/dt, or LAD pressure at any time point. Heart rates were comparable between the SPM-5185 and vehicle groups at control. Heart rate was lower in the SPM-5185 group after ischemia and reperfusion. The PRI was higher in the SPM-5185 group at control but was comparable to the vehicle group during ischemia. PRI was significantly lower than vehicle at 30 minutes and 270 minutes of reperfusion. Therefore, 02 demand indexed by PRI was comparable during ischemia and lower during reperfusion. LVEDP was similar between the two groups at control and was transiently increased in the SPM-5185 group at 30 minutes of reperfusion.
Regional Myocardial Blood Flow
Transmural myocardial blood flow is shown in Fig 3A  for the ischemic-reperfused zone and in Fig 3B for the nonischemic zone for baseline, 55 minutes of ischemia, and 270 minutes of reperfusion. There were no differences in baseline blood flows between groups or zones. In the ischemic-reperfused zone, coronary occlusion significantly reduced blood flow to comparable values in both groups (P=.98 versus groups), averaging 5.4+1.4 mL-min . 100 g-' in the vehicle group and 5.4+1.3 mL-min'-1 100 g`in the SPM-5185 group. After 270 minutes of reperfusion, blood flow in the vehicle group returned to 63% of its baseline value (P=.10 versus baseline). Blood flow in the SPM-5185 group was restored to values threefold greater than the vehicle group (P=.04). The modestly elevated blood flow in the nonischemic region (Fig 3B) of the SPM-5185 group relative to the vehicle group (which may have received some SPM-5185 from LAD coronary venous effluent spillover into the periphery) suggests that some vasodilation may have occurred secondary to SPM-5185 or that microvascular injury was reduced. Fig 3C shows the in vitro vasodilator dose-response curve to SPM-5185. These data confirm that SPM-5185 at 500 nmol/L concentration has a modest dilator capability compared with its nonnitrosylated counterpart.
Regional Function
The segmental function data for the vehicle and SPM-5185 groups are summarized in Table 1 systolic shortening is due to a hysteresis in the pressuresegment loop with systolic shortening insufficient to overcome initial systolic bulging as described previously.162223,25 Therefore, SPM-5185 treatment caused a modest but significant recovery of postischemic segmental work.
Segmental stiffness determined by end-diastolic pressure-segment length relations is summarized in Table 1 (Fig 7A) and ischemic-reperfused (Fig 7B) (Fig 7) . The adherence of unstimulated PMNs to coronary arteries subjected to 90 minutes of occlusion and 120 minutes of reperfusion was 115±15 PMNs/mm2 greater than that observed in the unstimulated coronary arteries. PMN adherence to ischemic-reperfused LAD coronary artery segments was very significantly (P<.001) reduced by SPM-5185 (27±5 PMNs/mm2), whereas SPM-5267 had no effect. Interestingly, nitroglycerin (500 nmol/L) did not influence PMN adherence to ischemic-reperfused LAD arteries (103 ±4 PMNs/mm2). In contrast, MAb R15.7 inhibited PMN adherence by nearly 70% (P<.001), a level that was comparable to PMN inhibition afforded by SPM-5185.
Effects of SPM-5185 on PMN-Induced Contraction
To determine the role of SPM-5185 on neutrophilmediated vasoconstriction, we studied the effects of the NO donor in an in vitro system of PMN-induced endothelial injury. Representative tracings from canine LAD coronary artery rings exposed to LTB4-activated PMNs are shown in Fig 8. In control rings (Fig 8A) , the addition of unstimulated canine PMNs (4x105 cells/ mL) to the organ bath did not elicit any contraction. The addition of 100 nmol/L LTB4 in the absence of PMNs produced no significant contraction of the coronary artery rings (data not shown). However, stimula- SPM-5185 at a concentration of 500 nmol/L significantly inhibited the PMN-induced contraction by 58% (P<.01 compared with control, Fig 8B) . (1 ,umol/L) failed to attenuate the PMN-mediated coronary artery contraction (Fig 8C) , suggesting that the donated NO was the active moiety. In addition, MAb R15.7 (20 gg/mL) significantly inhibited the PMN- The dilator responses to ACh, A23187, and NaNO2 for all coronary artery rings tested are summarized in Table 2 . LTB4-stimulated PMNs significantly attenuated endothelium-dependent vasorelaxation responses to ACh and A23187. In contrast, SPM-5185 (500 nmol/L) significantly reduced PMN-induced endothelial dysfunction. However, the nitrate-deficient analog SPM-5267 failed to demonstrate any preservation of the coronary endothelium relaxation. In addition, MAb R15.7 (20 ug/mL) completely prevented endothelial dysfunction by activated PMNs and restored post-PMN vasodilator capacity to pre-PMN levels. No significant changes were observed in the responses to the endothelium-independent vasodilator sodium nitrite at any time during the experimental protocol. Therefore, SPM-5185 prevented PMN-induced endothelial damage in a manner parallel to inhibition of PMN adherence. Discussion The results of the present study demonstrate that the organic NO-donating compound SPM-5185 exerts a cardioprotective effect in a canine model of ischemia and reperfusion. Treatment with 500 nmol/L intracoronary SPM-5185 at reperfusion only resulted in a significant (ie, 70%) reduction in myocardial necrosis relative to the untreated vehicle group. This reduction of infarct size was independent of collateral blood flow since infarct size was lower in the SPM-5185-treated group than in the vehicle group at comparable collateral blood flow. Group differences were not due to any interference of SPM-5185 with the TTC staining process per se. The infarct size reduction was confirmed by significant attenuation of CK release throughout the reperfusion period. In addition, intracoronary SPM-5185 treatment was associated with improved postischemic segmental work generation and avoidance of postischemic stiffness. Reduction of acute myocardial infarct size and avoidance of segmental systolic and diastolic dysfunction may be attributed in part to inhibition of neutrophil accumulation, possibly by directly inhibiting neutrophil adherence to coronary endothelium and attenuating neutrophil-dependent endothelial cell damage. The PMN-related effects most likely are due to released NO, since SPM-5267 had no effect on vasodilation or neutrophil activity.
SPM-5185 is a recently developed cysteine-containing mononitrate (Fig 1) dium. This attenuated neutrophil accumulation may be secondary to reduced neutrophil adherence to the coronary endothelium induced by SPM-5185 as demonstrated by the adherence data (Fig 7) . The reduced infarct size may therefore be due to inhibition of neutrophil-mediated endothelial and myocyte damage, possibly related to oxygen free radical generation.
Recently, McCall and coworkers13 have demonstrated that NO directly inhibits in vitro aggregation of rabbit PMNs. Consistent with these findings, Kubes et a114 reported that monomethyl arginine, an inhibitor of NO synthesis, markedly increased PMN adherence to the vascular endothelium. These findings support the concept that NO modulates PMN adherence to the endothelium. After myocardial ischemia and reperfusion, acetylcholine-or calcium ionophore-stimulated release of NO by cat coronary artery rings is markedly attenuated as early as 2.5 minutes after reperfusion and remains impaired for several hours.5 Additional studies conducted by Nichols et a13 and Van Benthuysen et a12 provide strong evidence that canine endothelial cells are also subject to injury after myocardial ischemia-reperfusion and suffer from an impairment of EDRF release. Therefore, it is likely that, after impaired NO release by the endothelium and accumulation of chemotactic factors at the time of reperfusion, local conditions favor the adherence of PMNs to the coronary endothelium. Our adherence data confirm the enhanced adherence of neutrophils to ischemic-reperfused coronary artery vascular endothelium (Fig 9B) .
To further define the antineutrophil properties of SPM-5185, the adherence of LTB4-stimulated PMNs to naive coronary artery endothelium was also investigated. The initial step in PMN In additional in vitro studies, we examined the effects of SPM-5185 on neutrophil-induced coronary endothelial dysfunction, manifested as vascular ring contraction produced by neutrophil-generated superoxide anions. This oxygen free radical production overwhelms the basal release of NO by the coronary vascular endothelium.6 Previous studies using isolated coronary arterial preparations and autologous PMNs from cats,62 dogs, 63 and humans6" have demonstrated profound vasoconstriction upon activation of the PMNs by a number of stimuli, including low-flow perfusion followed by a return to normal perfusion. Furthermore, these PMNinduced coronary artery contractions have been shown to be associated with endothelial dysfunction characterized by attenuated responses to endothelium-dependent vasodilators62 and are comparable to the PMNmediated coronary endothelial injury that occurs after MI-R.65 In the present study, SPM-5185 significantly inhibited the PMN-induced contraction of coronary artery rings and provided a significant degree of endothelial protection as assessed by the vasorelaxation responses to ACh and A23187. In contrast, the NOdeficient analog of SPM-5185 (SPM-5267) failed to provide any protection against the PMN-mediated vasoconstriction or subsequent endothelial injury to the coronary endothelium. These results provide additional evidence for a neutrophil-inhibitory effect of SPM-5185 that may have contributed significantly to the reduction of infarct size after ischemia-reperfusion.
Although authentic NO and this cysteine-containing NO donor clearly protect the ischemic myocardium from reperfusion injury, there are reports66'67 that NO can combine with superoxide radicals to form peroxynitrite, which is a toxic free radical species. It is highly unlikely that peroxynitrite could be involved in these experiments since very high concentrations of peroxynitrite (ie, 500 ,umol/L to 1 mmol/L) are required to produce cytotoxic effects in isolated liposomes.66 In the present study a 1000-fold lower intracoronary concentration (500 nmol/L) of this novel NO donor was found to be extremely cardioprotective in the early phase of reperfusion, which would suggest that peroxynitrite is not involved in the pathogenesis of myocardial reperfusion injury. Furthermore, peroxynitrite possesses a halflife on the order of 1 second, and it is unlikely that this short-lived free radical plays a significant role in reperfusion injury, which occurs over a number of hours. Most important, peroxynitrite has never been shown to be produced in an in vivo system during myocardial ischemia or reperfusion. Clearly, in our experiments, NO liberated from an NO-releasing agent, SPM-5185, was beneficial.
Conclusions
The present study demonstrates that the administration of the novel NO donor SPM-5185 at the time of reperfusion reduces the extent of cardiac cellular injury induced by severe regional myocardial ischemia. The mechanism of this cardioprotection appears to be largely related to inhibition of PMN adherence to the coronary endothelium and a reduction in the subsequent accumulation of activated PMNs in the ischemic myocardium. However, we cannot rule out that the modest vasodilation induced by SPM-5185 during reperfusion had a therapeutic effect, possibly by improving oxygen delivery or recruiting additional flow-dependent NO release. However, a recent study by VintenJohansen et a122 would rule out augmented flow as a primary mechanism of infarct size reduction during reperfusion. Since SPM-5185 may act at the microvascular level where bioconversion of nitroglycerin is limited, this cysteine-containing NO donor may be useful in targeting microvascular components of reperfusion injury. However, additional studies are necessary to further elucidate the precise mechanisms of cardioprotection exerted by NO donors in reperfusion injury. Additional studies using longer periods of reperfusion (ie, 24 or 48 hours) and histological assessment of infarct size are also clearly necessary to determine if SPM-5185 actually reduces the extent of myocardial cell injury or merely delays the onset of myocardial injury and infarct development.
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